Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

3×5 Partners

Founders Nicholas Walrod

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 13
Average round size
info
The average size of a deal this fund participated in
$32M
Portfolio companies 9
Rounds per year 1.18
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.08
Exits 2
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Electrical Distribution
Summary

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the 3x5 Partners, startups are often financed by RiverVest, Roche Venture Fund, Novo Ventures. The meaningful sponsors for the fund in investment in the same round are RiverVest, Roche Venture Fund, Samsara BioCapital.

The fund has exact preference in a number of founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Health Care, Food Processing. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Good Therapeutics, Allakos.

Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The increased amount of exits for fund were in 2018.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Angel Effect Istanbul, Kurucesme, Turkey
Asia Phoenix Investments -
CMA CGM France, Marseille, Provence-Alpes-Cote d'Azur
Energizer Missouri, St Louis, United States
Peapack-Gladstone Bank Bedminster, New Jersey, United States
ProofSystems -
RapidShare Entertainment Cham, Switzerland, Zug
Rockpoint Capital Boston, Massachusetts, United States
Zonff Partners -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Koya Medical

Biotechnology
Health Care
Internet
Pharmaceutical
$26M03 Feb 2022 Oakland, California, United States

Good Therapeutics

Biotechnology
Life Science
Pharmaceutical
$8M30 Dec 2021 Seattle, Washington, United States

Arch Oncology

Biotechnology
$105M27 Apr 2021 California, United States

Amplyx Pharmaceuticals

Biotechnology
Clinical Trials
Medical
Pharmaceutical
$53M19 May 2020 San Diego, California, United States

InterVene

Health Care
Medical
Medical Device
$15M25 Jun 2019 South San Francisco, California, United States

Allakos

Biopharma
Biotechnology
Health Care
Therapeutics
$100M13 Dec 2017 California, United States

Fishpeople Seafood

Food and Beverage
Food Processing
Wine And Spirits
$12M06 Jun 2017 Portland, Oregon, United States
News
Claros Technologies Raises $5M in Series A Funding

– Claros Technologies is a St. Paul, Minn.-based advanced materials company.
– The company closed an $5m Series A funding round.
– The round was led by 3×5 Partners.
– The new investment will be used to expand the applications of their technology at the scale required to address problems for which the world needs immediate solutions.

Arch Oncology Secures $105M Series C

– Arch Oncology, a clinical-stage immuno-oncology company, has closed a $105m Series C financing co-led by Eventide Asset Management, Cowen Healthcare Investments and current investor 3×5 Partners.
– New investors in the round included Adage Capital Management, Point72 Asset Management, Avego Healthcare Capital, FMB Research and Broadfin Holdings.
– The company’s existing investors, including Roche Venture Fund, RiverVest Venture Partners, and Lightchain also participated in the round.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent 3×5 Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 13
Average round size 32M
Rounds per year 1.18
Peak activity year 2017
Lead investments 2
Follow on index 0.08
Exits 2
Group Appearance index 0.92

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Koya Medical

Biotechnology
Health Care
Internet
Pharmaceutical
$26M03 Feb 2022 Oakland, California, United States

Good Therapeutics

Biotechnology
Life Science
Pharmaceutical
$8M30 Dec 2021 Seattle, Washington, United States

Arch Oncology

Biotechnology
$105M27 Apr 2021 California, United States

Amplyx Pharmaceuticals

Biotechnology
Clinical Trials
Medical
Pharmaceutical
$53M19 May 2020 San Diego, California, United States

InterVene

Health Care
Medical
Medical Device
$15M25 Jun 2019 South San Francisco, California, United States

Allakos

Biopharma
Biotechnology
Health Care
Therapeutics
$100M13 Dec 2017 California, United States

Fishpeople Seafood

Food and Beverage
Food Processing
Wine And Spirits
$12M06 Jun 2017 Portland, Oregon, United States
Crunchbase icon

Content report

The following text will be sent to our editors: